Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02027948
Other study ID # 13-264
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 23, 2013
Est. completion date March 1, 2022

Study information

Verified date March 2022
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with esophageal and gastroesophageal junction (GEJ) cancer often have weight loss, swallowing problems, and poor appetite. This may affect their ability to tolerate cancer treatment. The purpose of this study is to see if the researchers can apply a set of nutrition guidelines designed specifically for patients with cancer who are older than 65 years of age. The questions will allow them to assess the nutritional status and make appropriate referrals. If the patients are having swallowing problems or losing weight, the researchers want to address the nutritional problems early in the course of their treatment.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date March 1, 2022
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Patients must be = age of 65; no maximum age limit. - Patients who will receive induction chemotherapy followed by combined chemoradiotherapy at MSKCC for localized stage I-III esophageal or gastroesophageal junction cancer. - Patients can receive chemoradiotherapy preoperatively prior to surgical resection or as definitive/primary chemoradiotherapy. - Patients can be KPS =60, as long as primary provider feels that patient is candidate for combined modality chemoradiotherapy - Be able to provide informed consent Exclusion Criteria: - Enrolled on a phase I trial - Patients with a feeding tube previously placed. - Not English-speaking

Study Design


Related Conditions & MeSH terms


Intervention

Other:
nutritional and functional assessments
Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as "normal nutrition," "at risk for malnutrition," or "malnourished" & receive the appropriate intervention.

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only) Basking Ridge New Jersey
United States Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only) Commack New York
United States Memorial Sloan Kettering Cancer Center at Commack (Consent Only) Commack New York
United States Memorial Sloan Kettering West Harrison (Consent Only) Harrison New York
United States Memorial Sloan Kettering Monmouth (Consent Only) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Consent only) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary feasibility of a nutritional management algorithm Various validated assessments of nutritional status have been described. Nutritional status can be evaluated using: 1) anthropometric measures (i.e. weight loss, body mass index (BMI), triceps skin fold thickness, arm circumference), 2) immunological measurements (i.e. absolute lymphocyte count), and 3) serum protein markers (i.e. albumin, prealbumin, transferrin, and retinol-binding protein) 2 years
Secondary treatment toxicity of chemoradiotherapy Treatment toxicity of chemoradiotherapy will be summarized using descriptive statistics. Binomial proportions along with exact 95% confidence intervals will be estimated for proportions. Toxicity during the induction chemotherapy phase will be correlated with the baseline nutritional status (as determined by the MNA assessment) and baseline functional status using Fisher's exact test for categorical measures and Wilcoxon's rank sum test for numeric measures. Similarly, toxicity during chemoradiotherapy will be correlated with baseline MNA and functional status as well as with the malnutrition assessment using Fisher's exact test for categorical measures and Wilcoxon rank sum test for numeric measures. 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT01747707 - Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03221426 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Phase 3
Completed NCT02178956 - A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Phase 3
Active, not recruiting NCT02872116 - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Phase 3
Completed NCT02538562 - Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea N/A
Recruiting NCT05322577 - A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Phase 1
Terminated NCT01813253 - Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer Phase 3
Recruiting NCT06346392 - AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Phase 3
Recruiting NCT06250894 - Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction Phase 2
Active, not recruiting NCT04276493 - Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab Phase 1/Phase 2
Terminated NCT02726399 - Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Phase 2
Recruiting NCT05395780 - A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer Phase 2
Completed NCT02661971 - FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Phase 2/Phase 3
Completed NCT02581462 - FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Phase 2/Phase 3
Completed NCT00917462 - Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer Phase 2
Recruiting NCT05187182 - CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer Phase 1
Not yet recruiting NCT06411171 - Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: Phase 3